Skip to content
The Policy VaultThe Policy Vault

Ogsiveo (nirogacestat) — CareFirst (Caremark)

Desmoid tumors without progression with significant symptoms or in locations where progression would be morbid

Initial criteria

  • Authorization of 12 months may be granted for treatment of progressive, morbid, or symptomatic desmoid tumors as a single agent

Reauthorization criteria

  • Authorization of 12 months may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months